AstraZeneca and Merck present data from prostate cancer trial at ASCO 2018

The data showed that the combination of Lynparza and abiraterone can help patients with a specific form of prostate cancer to live for longer without their disease getting worse

cancer cell
Lynparza is what’s called a PARP inhibitor which prevents cancer cells from repairing damaged DNA, causing them to die

AstraZeneca PLC (LON:AZN) and Merck & Co Inc (NYSE:MRK) have presented data from Study 08 at the American Society of Clinical Oncology in Chicago.

The Phase II trial was looking at the effect of Lynparza in combination with abiraterone (A.K.A Zytiga) in patients with metastatic castration-resistant prostate cancer (mCRPC) – a type of prostate cancer which keeps growing despite testosterone levels being reduced to very low levels.

READ: Astra and Merck in oncology tie-up

The data showed that median radiologic progression-free survival (rPFS) – the length of time a patient lives with the disease without it getting worse – was 13.8 months in the combination arm compared to 8.2 months with abiraterone alone.

Over the long run, though, the combination therapy wasn’t much more effective in keeping patients alive for longer.

Median overall survival was 22.7 months in those taking both Lynparza and abiraterone versus 8.2 months in patients just taking the latter.

“There is a significant unmet medical need for patients with metastatic castration-resistant prostate cancer as they are a high-risk group with limited treatment options,” noted Merck’s chief medical officer Roy Baynes.

“Lynparza is the first PARP inhibitor to demonstrate activity in combination with standard-of-care treatment in prostate cancer,” noted Roy Baynes, senior vice president and head of Global Clinical Development, chief medical officer, MSD Research Laboratories.

AstraZeneca shares were broadly flat at £54.17 in early afternoon trading in London, while Merck’s stock was also unmoved in the pre-market in New York at US$62.02.

Quick facts: AstraZeneca

Price: 7217 GBX

Market: LSE
Market Cap: £94.68 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Things coming together nicely in Greenland, says Bluejay Mining's CEO

Rod McIllree, Bluejay Mining PLC’s (LON:JAY) chief executive, tells Proactive that all three of its projects in Greenland are shaping up nicely with plenty of interest from mining giants. Dundas is the flagship and here a bulk sample of mineral sands has been shipped to a Rio Tinto facility...

2 days, 15 hours ago

2 min read